NY-FRAME.IO
11.2.2021 20:32:07 CET | Business Wire | Press release
Frame.io , the world’s leading cloud-based video review and approval platform, today announced Frame.io Camera to Cloud (C2C) , a secure camera-to-cloud workflow that lets customers instantly upload and stream images from on-set cameras to creative post-production teams anywhere in the world. Frame.io C2C represents the largest change in film, television, news and commercial production workflows since the advent of digital filmmaking.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210211005854/en/
Customers can view the launch event on demand at the Frame.io website and sign up for the beta today. Frame.io C2C will be available this spring to all customers at no additional cost. Download the Frame.io C2C press kit here .
Frame.io C2C provides two unique services. First, C2C enables instant proxy uploads the moment cameras stop rolling so editorial can begin within seconds of calling “cut.” In addition, Frame.io C2C can live stream footage to an authorized user’s device on or off set, allowing customers to watch production as it’s happening. This is ideal for productions working during COVID, as it greatly reduces the number of people needed on set. Frame.io C2C lets editorial and other traditionally linear parts of the creative process happen in parallel while footage is still being shot.
Getting footage from a camera into post-production is a time-consuming process that requires backing up files, transferring them to a hard drive, and shipping them to another facility. Frame.io C2C eliminates that, letting customers simultaneously view a live stream of footage as it is being shot, while automatically capturing and uploading proxies as soon as the camera stops rolling.
The camera-to-cloud workflow requires a Frame.io C2C-certified device connected to compatible cameras from Arri, RED and Sony. Once authenticated, certified devices such as the Teradek CUBE 655 and Sound Devices 888 or Scorpio recorders will record, encode, and send timecode-accurate H.264 proxy files with matching filename metadata directly to Frame.io via an encrypted and secure connection using LTE, 5G or WiFi. This allows for near real-time delivery of editable proxy files to a producer, dailies facility, or editor anywhere in the world.
“Frame.io C2C is disruptive technology that changes the traditionally linear filmmaking process, allowing both on-set production and remote post-production teams to work together at the same time,” said Michael Cioni, Global SVP of Innovation at Frame.io. “This level of collaboration brings creative teams together and allows them to work faster and more collaboratively than ever before.”
In addition, Frame.io users with proper authentication credentials can view a live stream of footage while it's being shot from the comfort of their computer, iPhone, or iPad—whether they are on set or halfway around the world. This lets collaborators instantly share ideas to help bring their creative vision to life, while everyone who needs to track production progress can stay informed.
“In today’s socially distanced world—where remote work has become the norm and the number of people on-set is limited—Frame.io C2C is a game changer,” said Emery Wells, CEO of Frame.io. “Camera to Cloud gives film, television, and commercial productions a seamless new way for creative teams to do their best work, no matter where they are.”
Frame.io C2C features best-in-class security with full TPN and SOC 2 Type 2 compliance. Created by the MPAA and CDSA, TPN is the global, industry-wide initiative that defines requirements and best practices for protecting content. Combined with rigorous access controls, Frame.io C2C is an incredibly safe way to share media with authorized viewers and collaborators.
Also introduced today, the new Frame.io Cloud Devices API and C2C certification program enables hardware and software manufacturers to create their own C2C compatible products. Frame.io C2C is launching with three groundbreaking partner integrations from Teradek, Sound Devices, and Colorfront, making it compatible with more than a dozen professional camera systems from RED, Arri, and Sony.
Manufacturers interested in building Frame.io C2C Certified software and hardware can find details at developer.frame.io .
PRICING AND AVAILABILITY
C2C features are included at no additional charge for customers with a paid Frame.io account. Flexible, new monthly enterprise plans let customers and studios purchase the service they need for the duration of their production.
Frame.io C2C is currently in beta and will ship this spring. Customers can apply to participate in the beta program at the Frame.io website. Live streaming features will be available later in 2021.
FRAME.IO C2C LAUNCH PARTNERS
Teradek designs and manufactures high-performance video solutions for broadcast and cinema. A Frame.io authenticated CUBE 655 encoder delivers live streams and camera proxy files directly into Frame.io.
Sound Devices designs and manufactures the world’s leading production sound field recorders. The latest 888 and Scorpio recorders capture and transmit original audio files directly into Frame.io.
Colorfront has developed the world’s first fully cloud dailies platform. Their Express Dailies integration with Frame.io allows labs to instantly access the video and audio assets to create dailies.
ABOUT FRAME.IO
Frame.io is the world’s leading video review and approval platform with over 1 million users. Integrated with most major professional video tools, Frame.io streamlines the creative process by centralizing assets and feedback in the cloud. This allows remote creative teams to collaborate securely and in real time from anywhere in the world.
Conceived and designed in 2015 by video creators Emery Wells and John Traver, Frame.io is intuitive and simple, yet powerful enough for creative professionals, technical administrators, and clients to use with little (or no) training. Frame.io accelerates workflows and eliminates obstacles to creativity. From script or storyboard to dailies through delivery, Frame.io has reinvented the modern video workflow.
Frame.io is backed by industry heavyweights including Insight Partners, FirstMark Capital, and Accel Partners. To learn more please visit http://frame.io .
Watch: Frame.io C2C announcement
Download: Frame.io C2C Press Kit
Watch: What is Frame.io?
View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005854/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
